IPBS Supplement

IPBS 补充

• 批准号: 8291332
• 负责人: ROBERT E REITER
• 金额: --
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2013-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8291332
• 关键词: Adoption; Agreement; Biological Assay; Biological Markers; Biostatistics Core; Case Series; Clinical; Collection; Computer software; Diagnosis; Evaluation; Genes; Goals; Informatics; Institution; Malignant Neoplasms; Malignant neoplasm of prostate; Meta-Analysis; PTEN gene; Pathology; Process; Prospective Studies; Protocols documentation; Publications; Publishing; Research; Research Infrastructure; Retrospective Studies; Serum; Site; Slide; Solutions; Specimen Handling; Staining method; Stains; Technology; Tissue Fixation; Tissues; Work; Workplace; base; improved; meetings; men; molecular marker; open source; prospective; tool; working group

The goal of the IPBS is to validate tissue and serum biomarkers prospectively for clinical use. Although there is general agreement that molecular markers have the potential to improve the ability to diagnose and treat men with prostate cancer, to date none have achieved clinical utility. The SPORE solicited applications for candidate biomarkers. UCLA submitted applications on p27, PSCA, PTEN and other markers based on its track record of discovery and publication on these genes. The SPORE commissioned a meta-analysis of published work to prioritize biomarkers for both prospective and retrospective study. P27 was one of a small number of biomarkers chosen for prospective evaluation, with both UCLA and Dana Farber selected as sites for performing the assay. UCLA's Pathology and Biostatistics Core have been integrally involved in the IPBS. The Pathology Core participated in a prospective study to evaluate the effect of tissue fixation on biomarkers, submitting a series of cases to a central facility for processing. UCLA's Pathology Core has also agreed to participate fully in the study, including collection and processing of specimens according to the protocol. Slides for p27 will be sent to UCLA for staining and scoring. The IPBS was targeted as the first inter-SPORE study that would utilize the tools and infrastructure selected and developed for the NBN. The Cancer Biolnformatics Grid (caBIG) tool set referred to as the caTissue Suite was identified early on (in 2004) by an informatics team from several of the SPORE sites as an ideal software solution that would meet the needs of the NBN. However, the delivery of the caTissue suite was delayed to the point that the IPBS informatics working group elected to move forward with a short-term solution while each of the 11 sites works out details of implementation of caTissue at their respective institutions. UCLA has participated in this entire process, including the NBN informatics meetings, the IPBS informatics working group, and efforts to clarify adoption issues related to relevant caBIG tools. In addition, the IPBS informatics working group selected the open source protocol tracker software suite called pTracker developed at UCLA by the Computing Technologies Research Lab to support the IPBS needs until caTissue mature to the point that it and related tools can used.

IPBS的目标是前瞻性地验证组织和血清生物标记物是否可用于临床。尽管有 普遍认为分子标记有可能提高诊断和治疗男性的能力 对于前列腺癌，到目前为止还没有一种药物达到临床实用。孢子征集申请 候选生物标志物。加州大学洛杉矶分校基于ITS提交了关于p27、PSCA、PTEN和其他标记的申请 关于这些基因的发现和发表的跟踪记录。孢子公司委托进行了一项关于 发表了为前瞻性和回溯性研究确定生物标记物优先顺序的工作。P27是一个很小的 选择进行前瞻性评估的生物标记物的数量，加州大学洛杉矶分校和达纳·法伯都被选为地点 进行化验。 加州大学洛杉矶分校的病理学和生物统计学核心已经完整地参与了IPBS。病理学的核心 参与了一项评估组织固定对生物标记物影响的前瞻性研究，提交了一系列 案件被送到中央设施进行处理。加州大学洛杉矶分校的病理核心也同意全面参与 研究，包括根据议定书收集和处理标本。P27的幻灯片将发送到 UCLA用于染色和评分。 IPBS的目标是利用选定的工具和基础设施进行的第一次孢子间研究 并为NBN开发。癌症生物信息学网格(CaBIG)工具集，称为caTIssue套件 早在2004年就被来自几个孢子站点的信息学团队确定为理想的软件 满足NBN需求的解决方案。然而，caTIssue套件的交付被推迟到 指出，IPBS信息工作组选择推进一项短期解决方案，同时每个 这11个站点制定了在各自机构实施CATIssue的细节。加州大学洛杉矶分校有 参与了整个过程，包括NBN信息学会议、IPBS信息学工作组、 以及努力澄清与相关caBIG工具相关的采用问题。此外，IPBS信息学工作 小组选择了由加州大学洛杉矶分校开发的开源协议跟踪软件套件PTracker 计算技术研究实验室支持IPBS需求，直到CAT问题成熟到 并可使用相关工具。